Diferencia entre revisiones de «Diclofenac»
(Created page with "==General== *Type: NSAID *Dosage Forms: PO (18 and 35mg tabs) *Common Trade Names: Zorvolex ==Adult Dosing== Pain, mild-moderate *18-35mg PO TID Osteoarthritis *35mg PO...") |
|||
| (No se muestran 6 ediciones intermedias de 3 usuarios) | |||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: [[NSAID]] | *Type: [[NSAID]] | ||
*Dosage Forms: | *Dosage Forms: Capsule 18mg, 25mg, 35mg; ER Tablet 100mg, 0.1% opthalmic solution, topical gel 1-3% | ||
*Common Trade Names: Zorvolex | *Common Trade Names: Zorvolex | ||
==Adult Dosing== | ==Adult Dosing== | ||
Pain, mild-moderate | ===Pain, mild-moderate=== | ||
* | *Tablet PO 50mg TID, may administer 100mg as first dose | ||
Osteoarthritis | ===Ankylosing Spondylitis=== | ||
*PO Delayed Release 25mg 4x daily and 25mg qhs prn | |||
===[[Osteoarthritis]]=== | |||
*35mg PO TID | *35mg PO TID | ||
| Línea 17: | Línea 20: | ||
*[[Pregnancy Rating]]: C, category D if >30wks after gestation | *[[Pregnancy Rating]]: C, category D if >30wks after gestation | ||
*Lactation: probably safe | *Lactation: probably safe | ||
*Renal dosing: | *Renal dosing: monitor renal function closely if advanced renal disease | ||
*Hepatic dosing: max 54mg/day | |||
*Hepatic dosing | |||
==Contraindications== | ==Contraindications== | ||
*allergy to class/drug | *allergy to class/drug | ||
*ASA or NSAID-induced asthma or urticaria | *ASA or NSAID-induced asthma or urticaria | ||
* | *caution if: | ||
* | **renal impairment, dehydration, elderly or debilitated | ||
* | **history of GI bleed or ulcers, alcohol use, or coagulopathy | ||
* | **hepatic impairment | ||
* | **asthma | ||
* | **cardiovascular disease (or high risk of), including CABG surgery periop use, recent MI, CHF, HTN, smoker | ||
* | **fluid retention | ||
* | **PKU | ||
**prolonged use | |||
* | |||
* | |||
* | |||
* | |||
* | |||
* | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
'''Serious''' | '''Serious''' | ||
*GI bleeding | *GI bleed, ulcer, perforation | ||
* | *blood dyscrasias, prolonged bleeding time, anemia | ||
*MI | *nephrotoxicity, renal papillary necrosis | ||
*MI, stroke, thromboembolism, HTN, CHF | |||
*hepatotoxicity, hepatic necrosis, pancreatitis | |||
*hepatotoxicity | |||
*bronchospasm | *bronchospasm | ||
*exfoliative dermatitis | *exfoliative dermatitis, SJS/TEN | ||
'''Common''' | '''Common''' | ||
*dyspepsia | *dyspepsia, nausea/vomiting, abdominal pain, diarrhea, constipation, flatulence | ||
*headache, dizziness, drowsiness, tinnitus | |||
*headache | |||
*dizziness | *dizziness | ||
*rash | *rash, pruritus, urticaria, photosensitivity | ||
*fluid retention, peripheral edema | |||
*fluid retention | |||
*ecchymosis | *ecchymosis | ||
*elevated creatinine, ALT/AST | |||
*sinusitis | *sinusitis | ||
==Pharmacology== | ==Pharmacology== | ||
| Línea 99: | Línea 63: | ||
==See Also== | ==See Also== | ||
[[NSAID]] | *[[NSAID]] | ||
*[[NSAID toxicity]] | |||
[[Category: Pharmacology]] | [[Category: Pharmacology]] | ||
Revisión actual - 22:34 26 ene 2019
General
- Type: NSAID
- Dosage Forms: Capsule 18mg, 25mg, 35mg; ER Tablet 100mg, 0.1% opthalmic solution, topical gel 1-3%
- Common Trade Names: Zorvolex
Adult Dosing
Pain, mild-moderate
- Tablet PO 50mg TID, may administer 100mg as first dose
Ankylosing Spondylitis
- PO Delayed Release 25mg 4x daily and 25mg qhs prn
Osteoarthritis
- 35mg PO TID
Pediatric Dosing
NA
Special Populations
- Pregnancy Rating: C, category D if >30wks after gestation
- Lactation: probably safe
- Renal dosing: monitor renal function closely if advanced renal disease
- Hepatic dosing: max 54mg/day
Contraindications
- allergy to class/drug
- ASA or NSAID-induced asthma or urticaria
- caution if:
- renal impairment, dehydration, elderly or debilitated
- history of GI bleed or ulcers, alcohol use, or coagulopathy
- hepatic impairment
- asthma
- cardiovascular disease (or high risk of), including CABG surgery periop use, recent MI, CHF, HTN, smoker
- fluid retention
- PKU
- prolonged use
Adverse Reactions
Serious
- GI bleed, ulcer, perforation
- blood dyscrasias, prolonged bleeding time, anemia
- nephrotoxicity, renal papillary necrosis
- MI, stroke, thromboembolism, HTN, CHF
- hepatotoxicity, hepatic necrosis, pancreatitis
- bronchospasm
- exfoliative dermatitis, SJS/TEN
Common
- dyspepsia, nausea/vomiting, abdominal pain, diarrhea, constipation, flatulence
- headache, dizziness, drowsiness, tinnitus
- dizziness
- rash, pruritus, urticaria, photosensitivity
- fluid retention, peripheral edema
- ecchymosis
- elevated creatinine, ALT/AST
- sinusitis
Pharmacology
- Half-life: 1.9 hours
- Metabolism: liver; CYP450 (2C8, 2C9, 3A4 substrate), UGT (2B7 substrate)
- Excretion: urine 65%, bile 35%
- Mechanism of Action: exact MOA unknown; inhibits cyclooxyrgenase, reducing prostaglandin and thromboxane synthesis
